Literature DB >> 20629124

Cognitive and functional decline in Huntington's disease: dementia criteria revisited.

Guerry M Peavy1, Mark W Jacobson, Jody L Goldstein, Joanne M Hamilton, Amy Kane, Anthony C Gamst, Stephanie L Lessig, J C Lee, Jody Corey-Bloom.   

Abstract

The importance of designating criteria for diagnosing dementia lies in its implications for clinical treatment, research, caregiving, and decision-making. Dementia diagnosis in Huntington's disease (HD) is often based on criteria developed for Alzheimer's disease requiring memory loss. However, it is likely that other cognitive deficits contribute to functional impairment in HD before memory declines. The goal is to identify cognitive deficits that contribute to functional impairment to support dementia criteria that reflect HD neuropathology. Eighty-four HD mutation-positive subjects completed neuropsychological tests and the Unified Huntington's Disease Rating Scale Functional Independence Scale (FIS). Functional impairment was defined as 80 or below on the FIS. Speed of processing, initiation, and attention measures accounted for 70.0% of the variance in FIS ratings (linear regression) and correctly classified 91.7% of subjects as functionally impaired or intact (logistic regression). Measures of memory, motor impairment except dysarthria, neuroleptic use, and depressed mood did not improve prediction. A definition of HD dementia that includes cognitive impairment in at least two areas of cognition but does not require a memory deficit, in the context of impaired functional abilities and a deteriorating course, more accurately reflects HD neuropathology and could lead to improved research methods and patient care.

Entities:  

Mesh:

Year:  2010        PMID: 20629124      PMCID: PMC2910142          DOI: 10.1002/mds.22953

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  30 in total

Review 1.  Aging and measures of processing speed.

Authors:  T A Salthouse
Journal:  Biol Psychol       Date:  2000-10       Impact factor: 3.251

2.  Behavioural abnormalities contribute to functional decline in Huntington's disease.

Authors:  J M Hamilton; D P Salmon; J Corey-Bloom; A Gamst; J S Paulsen; S Jerkins; M W Jacobson; G Peavy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

3.  Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity.

Authors:  Carissa Nehl; Jane S Paulsen
Journal:  J Nerv Ment Dis       Date:  2004-01       Impact factor: 2.254

4.  Huntington's dementia. Clinical and neuropsychological features.

Authors:  E D Caine; R D Hunt; H Weingartner; M H Ebert
Journal:  Arch Gen Psychiatry       Date:  1978-03

5.  Bradykinesia in early Huntington's disease.

Authors:  R Sánchez-Pernaute; G Künig; A del Barrio Alba; J G de Yébenes; P Vontobel; K L Leenders
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

6.  Apathy and disinhibition in frontotemporal dementia: Insights into their neural correlates.

Authors:  G Zamboni; E D Huey; F Krueger; P F Nichelli; J Grafman
Journal:  Neurology       Date:  2008-09-02       Impact factor: 9.910

7.  Psychomotor, executive, and memory function in preclinical Huntington's disease.

Authors:  J S Snowden; D Craufurd; J Thompson; D Neary
Journal:  J Clin Exp Neuropsychol       Date:  2002-04       Impact factor: 2.475

8.  Profile of cognitive progression in early Huntington's disease.

Authors:  A K Ho; B J Sahakian; R G Brown; R A Barker; J R Hodges; M-N Ané; J Snowden; J Thompson; T Esmonde; R Gentry; J W Moore; T Bodner
Journal:  Neurology       Date:  2003-12-23       Impact factor: 9.910

9.  Huntington's disease: clinical correlates of disability and progression.

Authors:  N Mahant; E A McCusker; K Byth; S Graham
Journal:  Neurology       Date:  2003-10-28       Impact factor: 9.910

10.  An assessment of verbal recall, recognition and fluency abilities in patients with Huntington's disease.

Authors:  N Butters; J Wolfe; E Granholm; M Martone
Journal:  Cortex       Date:  1986-03       Impact factor: 4.027

View more
  30 in total

Review 1.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

Review 2.  Progress in developing transgenic monkey model for Huntington's disease.

Authors:  Brooke R Snyder; Anthony W S Chan
Journal:  J Neural Transm (Vienna)       Date:  2017-11-10       Impact factor: 3.575

3.  Does pallidal neuromodulation influence cognitive decline in Huntington's disease?

Authors:  Emily Sanrey; Valérie Macioce; Victoria Gonzalez; Laura Cif; Fabienne Cyprien; Emilie Chan Seng; Philippe Coubes; Gaetan Poulen
Journal:  J Neurol       Date:  2020-09-04       Impact factor: 4.849

Review 4.  Huntington disease: natural history, biomarkers and prospects for therapeutics.

Authors:  Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi
Journal:  Nat Rev Neurol       Date:  2014-03-11       Impact factor: 42.937

Review 5.  Cognitive impairment in Huntington disease: diagnosis and treatment.

Authors:  Jane S Paulsen
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

6.  HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).

Authors:  N E Carlozzi; S G Schilling; J-S Lai; J S Paulsen; E A Hahn; J S Perlmutter; C A Ross; N R Downing; A L Kratz; M K McCormack; M A Nance; K A Quaid; J C Stout; R C Gershon; R E Ready; J A Miner; S K Barton; S L Perlman; S M Rao; S Frank; I Shoulson; H Marin; M D Geschwind; P Dayalu; S M Goodnight; D Cella
Journal:  Qual Life Res       Date:  2016-08-13       Impact factor: 4.147

7.  Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?

Authors:  N E Carlozzi; S Schilling; A L Kratz; J S Paulsen; S Frank; J C Stout
Journal:  Qual Life Res       Date:  2018-06-16       Impact factor: 4.147

8.  Sleep and circadian dysfunction in neurodegenerative disorders: insights from a mouse model of Huntington's disease.

Authors:  Dika Kuljis; Analyne M Schroeder; Takashi Kudo; Dawn H Loh; David L Willison; Christopher S Colwell
Journal:  Minerva Pneumol       Date:  2012-09

9.  Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.

Authors:  Xin Sun; Leonard O Marque; Zachary Cordner; Jennifer L Pruitt; Manik Bhat; Pan P Li; Geetha Kannan; Ellen E Ladenheim; Timothy H Moran; Russell L Margolis; Dobrila D Rudnicki
Journal:  Hum Mol Genet       Date:  2014-07-04       Impact factor: 6.150

10.  Everyday cognition in prodromal Huntington disease.

Authors:  Janet K Williams; Ji-In Kim; Nancy Downing; Sarah Farias; Deborah L Harrington; Jeffrey D Long; James A Mills; Jane S Paulsen
Journal:  Neuropsychology       Date:  2014-07-07       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.